newsfilter
← Earnings
Earnings Releases·

Absci Corporation — Third Quarter 2026 Earnings Summary

Absci Corporation reported third-quarter 2026 financial results showing $0.3 million in revenue and a net loss of $33.3 million. The company advanced its ABS-201 program for pattern hair loss, with 13-week interim proof-of-concept data anticipated in December 2026, and announced plans for a Phase 2 trial in endometriosis to begin in mid-2027. Absci appointed Gerry Muhle as Chief Commercial Officer to support the commercialization of its pipeline. As of September 30, 2026, the company held $173.7 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the second half of 2028.

Company
ABSCI CORP
Sector
Healthcare
Industry
Biotechnology